Table 3

Change in symptom severity score two weeks after treatment initiation, measured by patient symptom questionnaire (visual analogue scale, VAS): % of patients whose severity score changed

		ABT-229 (mg bid)
	Placebo	1.25	2.5	5.0	10.0
Postprandial fullness
Worsened	18	14	21	29	30
Improved	82	82	79	67	67
Bloating
Worsened	20	4^3-150	21	31	41^3-150
Improved	77	88	75	67	57
Epigastric pain
Worsened	25	24	23	33^3-160	46^3-150
Improved	70	65	66	49	44
Postprandial nausea
Worsened	18	24	21	25	35^3-160
Improved	77	71	70	69	63
Daytime heartburn
Worsened	16	25	28	33^3-160	31^3-160
Improved	66	61	58	54	50
Night-time regurgitation
Worsened	20	25	25	29^3-160	30^3-160
Improved	66	55	45	42	43

↵3-150 p⩽0.05,
↵3-160 0.05<p⩽0.1 versus placebo.